Protocol for the use of anti-SARC-CoVID-2 monoclonal antibodies Bamlanivimab + Etesevimab

0
30

Bamlanivimab + Etesevimab are anti-SARC-COVID-2 monoclonal antibodies that have received US FDA Emergency Use Authorization (EUA) and Department of Drug Administration (DDA) Conditional Use Approval. ..

the post Protocol for the use of anti-SARC-CoVID-2 monoclonal antibodies Bamlanivimab + Etesevimab appeared first on Public health update.

LEAVE A REPLY

Please enter your comment!
Please enter your name here